Apremilast, the second PDE4 inhibitor on the marker, was licensed in 2014 for adult patients with active PsA and patients with moderate-to-severe plaque psoriasis who were candidates for phototherapy or systemic therapy (Chiricozzi et al., 2016). This evidence concerns the gene PDE4A and psoriasis vulgaris.